ECErica Caffarini

Erica Caffarini

*This is an algorithmically generated author record based on publicly available information.

Erica Caffarini has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Initial Heparin Rates on Reaching Goal Anti-Xa and Activated Partial Thromboplastin Time Within 48 Hours of Initiation in Patients With Mechanical Circulatory Support

    by Jordan Orchard, Erica Caffarini, Angela Harding, Ashley Schuler, Marie M. Lockhart, John Dillis, Alyssa Meester

    Background: Patients receiving mechanical circulatory support (MCS) devices should receive anticoagulation to avoid clotting of the circuit and to lower risk of acute thrombosis. Patients at our institution are initiated on UFH at 12 units/kg/h; however, patients weighing > 83 kg are weight-capped (WC) at an initial rate of 1000 units/h, which equates to < 12 units/kg/h. Objective: The objective of this study was to compare time to goal anticoagulation in patients receiving MCS who were WC compared to those who were not. Methods: A retrospective cohort study was completed of patients who received UFH during admission for an MCS device and monitored by activated partial thromboplastin time (aPTT) or anti-Xa levels. The primary outcome was the percentage of patients between groups who achieved goal anti-Xa or aPTT within 48 h of UFH initiation. Results: A total of 56 patients were included, with 27 not weight-capped (NWC) and 29 WC. There was no significant difference between groups in percentage of patients who achieved goal anti-Xa or aPTT within 48 h (88.9% NWC vs 89.7% WC, P = 0.93). There was no significant difference in time to goal between groups. The NWC group had more bleeding events (4 vs 0, P = 0.031), with no difference in thrombosis. Conclusion: There was no difference in the percentage of patients reaching goal aPTT or anti-Xa within 48 h when UFH was WC. However, future studies should compare differences in time to goal anticoagulation between different UFH intensity protocols.

  • Beyond the Bedside: Utilization of an On-Call Pharmacist to Bridge Gaps in Clinical Coverage for Select Critically ill Populations

    by Alyssa S. Meester, Erica Caffarini, Mariela Cardona Gonzalez, Michael Young, Jordan DeWitt

    Purpose: To describe the utilization of an on-call critical care pharmacist to bridge gaps in clinical coverage for subspecialized critically ill populations. Methods: In October 2022, a 24/7 on-call team of medical and cardiac ICU pharmacists was established to field questions regarding patients with mechanical circulatory support and pulmonary hypertension. On-call pharmacists were available via centralized telephone number Monday through Friday from 4:00 p.m. to 8:00 a.m., and at all hours on weekends. Information characterizing calls received was collected in an electronic database. A review of all database entries through March 2025 was conducted and descriptive statistics were used to quantify calls received, time spent, multidisciplinary team member engagement, and types of interventions. Results: On-call pharmacists received 207 calls and documented 218 interventions. Calls were most often received between the hours of 4:00 p.m. and 8:00 a.m., and the median time spent per call was 10 minutes (IQR 5-20 minutes). On-call critical care pharmacists received the most calls for ECMO patients (38.2%), followed by pulmonary hypertension (26.1%) and Impella® patients (20.8%). The majority of inquiries were from pharmacists (35.7%), followed by advanced practice providers (33.3%) and physicians (21.3%). Anticoagulation and hemostasis was the most commonly cited intervention category (56.4%). Conclusion: In the absence of an onsite critical care pharmacist, a 24/7 on-call critical care pharmacist was utilized by members of the multidisciplinary team to bridge gaps in clinical coverage. Further research is needed to determine the pharmacoeconomic and clinical impacts of on-call critical care pharmacists when onsite resources are unavailable.